Immunitybio Receives UAE Marketing Authorization For Anktiva In Bladder and Lung Cancer
IBRX•UAE authorization for Anktiva
July 29 (Reuters) - Immunitybio Inc IBRX.O:
- Immunitybio receives United Arab Emirates (UAE) marketing authorization for Anktiva® across BCG-unresponsive non-muscle invasive bladder cancer for CIS and papillary disease and metastatic non-small cell lung cancer
Source text: ID:nBw1Hg1Mwa
